CVS booting Zep from Preferred Coverage

Quote

anonymous

Guest
Novo is getting desperate, pigeonholing themselves with CVS. Sure, CVS is the largest retail pharmacy chain in the US but retail pharma are struggling and Novo doesn't have an equialent direct-to-consumer path that's as streamlined as us with Lilly Direct and Amazon Pharmacy shipped right to your door. Really curious how this will impact our strategy moving forward.
 


anonymous said:
Novo is getting desperate, pigeonholing themselves with CVS. Sure, CVS is the largest retail pharmacy chain in the US but retail pharma are struggling and Novo doesn't have an equialent direct-to-consumer path that's as streamlined as us with Lilly Direct and Amazon Pharmacy shipped right to your door. Really curious how this will impact our strategy moving forward.
Click to expand...
Not sure how or if it will impact strategy, but it should impact other things like: incentive compensation, goals and routing optimization with DT.
 












Major problem for Zepbound. Not covered on the largest employer in the nation-federal, and the largest PBM in the nation-cvs Caremark. Top that off with can’t produce CV benefit and just a matter of time before ESI and Optum join in. Just a recipe for disaster. Lilly is pigeon holed for cash only which Is the worst because no one can afford 400 a month. I’d really be concerned of the future of Zepbound and also Monjaro as the competition has cvd and ckd indication. Why would a provider choose M over O. Stupid if they do.
 


anonymous said:
Major problem for Zepbound. Not covered on the largest employer in the nation-federal, and the largest PBM in the nation-cvs Caremark. Top that off with can’t produce CV benefit and just a matter of time before ESI and Optum join in. Just a recipe for disaster. Lilly is pigeon holed for cash only which Is the worst because no one can afford 400 a month. I’d really be concerned of the future of Zepbound and also Monjaro as the competition has cvd and ckd indication. Why would a provider choose M over O. Stupid if they do.
Click to expand...
It's 500/month. 349 for the first month to get 'em hooked.
 


anonymous said:
Major problem for Zepbound. Not covered on the largest employer in the nation-federal, and the largest PBM in the nation-cvs Caremark. Top that off with can’t produce CV benefit and just a matter of time before ESI and Optum join in. Just a recipe for disaster. Lilly is pigeon holed for cash only which Is the worst because no one can afford 400 a month. I’d really be concerned of the future of Zepbound and also Monjaro as the competition has cvd and ckd indication. Why would a provider choose M over O. Stupid if they do.
Click to expand...
I am thinking the same. Patients are not aware, they still think zepbound has same benefit as pure semiglutide with additional weight loss. Insurance companies are smart. They know that they will have to cover wegovy for other indications which zepbound won’t have, so why cover two and reduce volume discount. Rick is so arrogant. May be he can tone down on the fight and building Lilly’s share price for perfection.
 


anonymous said:
I am thinking the same. Patients are not aware, they still think zepbound has same benefit as pure semiglutide with additional weight loss. Insurance companies are smart. They know that they will have to cover wegovy for other indications which zepbound won’t have, so why cover two and reduce volume discount. Rick is so arrogant. May be he can tone down on the fight and building Lilly’s share price for perfection.
Click to expand...
I disagree. Patients LOVE the weight loss on Zep and they rarely care for outcomes. When we sold Jardiance, docs could barely talk patients into taking it for outcomes. They don’t think about future, they just want a better now. Think about the billions of $$ people spend on supplements and snake oils-no outcomes data, no insurance coverage. There’s plenty of market. In my area cash option is super popular
 


anonymous said:
I disagree. Patients LOVE the weight loss on Zep and they rarely care for outcomes. When we sold Jardiance, docs could barely talk patients into taking it for outcomes. They don’t think about future, they just want a better now. Think about the billions of $$ people spend on supplements and snake oils-no outcomes data, no insurance coverage. There’s plenty of market. In my area cash option is super popular
Click to expand...
Are all these cash 500/month? Which area? I suppose because their employer insurance doesn’t cover or because they don’t have good insurance (how are they affording this if can’t afford good insurance)?
 


anonymous said:
Are all these cash 500/month? Which area? I suppose because their employer insurance doesn’t cover or because they don’t have good insurance (how are they affording this if can’t afford good insurance)?
Click to expand...
Yes, people are paying $500/month. Plenty of areas in this country have well-enough to do population. Big cities with good jobs, and patients find money, because this product is that life-changing
 




anonymous said:
Yes, people are paying $500/month. Plenty of areas in this country have well-enough to do population. Big cities with good jobs, and patients find money, because this product is that life-changing
Click to expand...
Yes, but it’s a known fact, patients paying “cash” have much lower stay times than those using insurance.
 


anonymous said:
I am thinking the same. Patients are not aware, they still think zepbound has same benefit as pure semiglutide with additional weight loss. Insurance companies are smart. They know that they will have to cover wegovy for other indications which zepbound won’t have, so why cover two and reduce volume discount. Rick is so arrogant. May be he can tone down on the fight and building Lilly’s share price for perfection.
Click to expand...
We really screwed the pooch on this negotiation.
 



Write your reply...
Top Bottom
Back
Quote